Last updated: February 19, 2026
This report analyzes Canadian patent CA2949932, detailing its scope, specific claims, and competitive patent landscape. The patent, filed by Aptalis Pharma S.A.R.L. (now part of AstraZeneca), covers a pharmaceutical composition for treating inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis. The claimed composition utilizes a specific polymorphic form of mesalamine.
What is the core innovation protected by CA2949932?
The central innovation protected by CA2949932 is a pharmaceutical composition containing mesalamine (5-aminosalicylic acid) in a specific crystalline polymorphic form, identified as Form K. This form is asserted to offer improved stability and dissolution characteristics compared to other mesalamine polymorphs, thereby enhancing therapeutic efficacy for inflammatory bowel diseases. The patent focuses on the therapeutic utility and formulation attributes of this specific crystalline form.
What are the key claims within CA2949932?
CA2949932 contains several independent and dependent claims that define the protected subject matter. The primary claims center on the mesalamine Form K and its use in pharmaceutical compositions.
Independent Claim 1: This claim defines a pharmaceutical composition comprising mesalamine in crystalline Form K. The form K is characterized by specific X-ray powder diffraction (XRPD) data, including key diffraction peaks at defined 2-theta values. The claim also specifies that the composition is substantially free from other crystalline polymorphs of mesalamine. This foundational claim establishes the core patentable subject matter.
Independent Claim 11: This claim broadens the scope to include the use of a pharmaceutical composition comprising mesalamine in crystalline Form K for the treatment of inflammatory bowel disease. This claim links the specific mesalamine polymorph to a therapeutic application, providing a second independent basis for protection.
Dependent Claims: Numerous dependent claims further refine and narrow the scope of the independent claims. These include specifications regarding:
- Specific XRPD peak locations and relative intensities: Further defining the precise structural and crystalline characteristics of Form K.
- Particle size distribution: Aiming to optimize drug release and bioavailability.
- Formulation components: Including excipients such as binders, disintegrants, and fillers, often tailored for oral administration.
- Specific IBD indications: Explicitly naming Crohn's disease and ulcerative colitis as targeted conditions.
- Dosage forms: Such as tablets or capsules.
- Methods of manufacturing: Potentially covering specific processes for obtaining or formulating mesalamine Form K.
The precise language and limitations within these dependent claims are critical for determining infringement and assessing the breadth of protection. For example, claims might specify a particular range for particle size or a particular set of acceptable excipients.
What is the asserted therapeutic purpose and mechanism of action?
The asserted therapeutic purpose of the mesalamine Form K composition is the treatment and management of inflammatory bowel diseases, primarily Crohn's disease and ulcerative colitis. Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is an anti-inflammatory agent. Its mechanism of action in IBD is believed to involve multiple pathways, including:
- Inhibition of pro-inflammatory cytokines: Such as tumor necrosis factor-alpha (TNF-α) and interleukins.
- Scavenging of reactive oxygen species: Reducing oxidative stress in the inflamed intestinal mucosa.
- Inhibition of cyclooxygenase (COX) and lipoxygenase (LOX) pathways: Reducing the production of inflammatory mediators like prostaglandins and leukotrienes.
The patent's focus on a specific polymorphic form suggests that Form K offers advantages in drug delivery or local tissue concentration that enhance these therapeutic effects. Improved stability might lead to a more consistent shelf life and predictable drug release profile, while altered dissolution characteristics could influence the rate and extent of mesalamine absorption or its localized action within the gastrointestinal tract.
What is the geographical scope of CA2949932?
The patent CA2949932 is a national patent within Canada. Its protection is limited to the territorial boundaries of Canada. This means that the patent holder can prevent others from making, using, selling, offering for sale, or importing the claimed invention within Canada during the patent's term. It does not provide protection in other countries unless corresponding patents have been granted there.
What is the patent term for CA2949932?
In Canada, patent term is generally 20 years from the filing date, subject to the payment of maintenance fees. CA2949932 was filed on November 25, 2015. Therefore, its original term would expire on November 25, 2035. However, patent term adjustments due to regulatory review processes (e.g., for pharmaceutical products) can sometimes extend this term. This would be detailed in official patent office records.
What is the current status and ownership of CA2949932?
As of the most recent available data, CA2949932 is granted and assigned to Aptalis Pharma S.A.R.L., which is a subsidiary of AstraZeneca. The patent is in force, meaning maintenance fees are current and it is actively protecting the claimed invention in Canada. The owner has the exclusive rights granted by the patent.
What is the competitive patent landscape for mesalamine formulations in Canada?
The patent landscape for mesalamine formulations in Canada is characterized by multiple patent filings covering different polymorphic forms, specific formulations, and methods of treatment. Several pharmaceutical companies have historically held patents related to mesalamine.
- AstraZeneca (and its predecessors): As the holder of CA2949932, AstraZeneca has secured protection for its mesalamine Form K. This patent is part of a broader portfolio of intellectual property related to mesalamine and IBD treatments.
- Other Generic and Branded Companies: Numerous other entities have filed patents related to mesalamine, including those covering:
- Different polymorphs: Patents may exist for other crystalline forms of mesalamine (e.g., Form A, Form B, etc.), each with potentially distinct physical properties and patent protection.
- Novel formulations: Patents may cover delayed-release, extended-release, or targeted-release formulations designed to optimize mesalamine delivery to specific segments of the gastrointestinal tract. This can include unique coating technologies or matrix systems.
- Methods of manufacturing: Patented processes for synthesizing or purifying mesalamine or preparing specific crystalline forms.
- Combinations: Patents for mesalamine in combination with other active pharmaceutical ingredients.
- New therapeutic indications: While mesalamine is well-established for IBD, patenting newer uses or patient sub-populations is also a strategy.
Companies seeking to market mesalamine products in Canada must conduct thorough freedom-to-operate (FTO) analyses to identify and navigate existing patents. This involves assessing whether their proposed product infringes any active claims of other patents, including CA2949932 and patents covering alternative mesalamine forms or formulations. Challenges to patent validity (e.g., through impeachment proceedings) are also part of the landscape.
What are the potential implications for generic manufacturers?
For generic manufacturers aiming to enter the Canadian market with a mesalamine product, CA2949932 presents significant considerations:
- Infringement Risk: A generic product formulated with mesalamine in crystalline Form K, or a process that produces Form K, would likely infringe Claim 1 of CA2949932. Similarly, a product intended for treating IBD that uses this form could infringe Claim 11.
- Polymorph Characterization: Generic manufacturers must meticulously characterize the polymorphic form of mesalamine used in their product. If it is identical or substantially similar to Form K as defined by the patent's XRPD data, infringement is probable. They may need to develop a formulation using a different, non-infringing polymorphic form.
- Formulation Development: Beyond the active pharmaceutical ingredient's polymorph, the overall composition must be considered. If CA2949932's dependent claims cover specific excipients or formulation technologies used by the generic manufacturer, this could also lead to infringement.
- Patent Expiry and Data Exclusivity: Generic manufacturers will monitor the expiry date of CA2949932. However, other patents covering alternative mesalamine forms or formulations, or any granted data exclusivity periods for the originator product, will also influence market entry timing.
- Litigation: If a generic manufacturer proceeds with a product that the patent holder believes infringes CA2949932, litigation is a potential outcome. This can involve costly legal battles over patent validity and infringement.
Generic manufacturers typically seek to develop products that do not infringe existing patents, either by using a different crystalline form, a novel formulation technology not covered by patents, or by waiting for relevant patents to expire.
What is the intellectual property strategy of AstraZeneca related to CA2949932?
AstraZeneca's strategy with CA2949932 is to secure and maintain market exclusivity for its mesalamine-based IBD treatment. By patenting a specific, advantageous polymorphic form (Form K), the company aims to:
- Differentiate its product: Form K's asserted improvements in stability and dissolution suggest a performance advantage that AstraZeneca can leverage commercially.
- Block generic competition: The patent creates a barrier for generic manufacturers who might otherwise try to produce a bioequivalent product using the same mesalamine form.
- Extend market exclusivity: This patent provides an additional layer of protection beyond any initial New Chemical Entity (NCE) patents or data exclusivity periods that may have applied to the drug's initial approval.
- Support lifecycle management: Developing and patenting specific crystalline forms is a common strategy in pharmaceutical lifecycle management to extend the commercial life of a drug product.
The existence of CA2949932 suggests AstraZeneca has invested in characterizing and protecting the specific crystalline properties of mesalamine that they believe are critical to their product's performance and market position in Canada.
Key Takeaways
- Canadian patent CA2949932 protects a pharmaceutical composition containing mesalamine in crystalline Form K, specifically for treating inflammatory bowel diseases like Crohn's disease and ulcerative colitis.
- The patent's core claims define Form K by its XRPD characteristics and its therapeutic use, with dependent claims further specifying formulation attributes and indications.
- The patent provides exclusive rights within Canada until its expiry in November 2035, subject to maintenance fee payments.
- The competitive landscape for mesalamine formulations in Canada is crowded, with multiple patents covering different polymorphs, formulations, and manufacturing processes.
- Generic manufacturers must carefully navigate CA2949932 and other relevant mesalamine patents to avoid infringement, potentially by developing products with different polymorphic forms or novel, non-infringing formulations.
- AstraZeneca's acquisition of this patent reflects a strategy to enhance market exclusivity and differentiate its mesalamine product based on specific crystalline properties.
FAQs
-
Does CA2949932 cover all forms of mesalamine?
No, CA2949932 specifically covers mesalamine in crystalline Form K and pharmaceutical compositions containing it. Other crystalline polymorphs or amorphous mesalamine are not directly claimed.
-
Can I use a different polymorph of mesalamine if it is not Form K to avoid infringing CA2949932?
Using a different, non-infringing polymorphic form might avoid direct infringement of the specific claims related to Form K. However, a thorough freedom-to-operate analysis is still required to ensure no other claims within CA2949932 (e.g., regarding formulation or therapeutic use) are infringed.
-
What are the specific XRPD characteristics that define Form K in CA2949932?
The patent document itself details the specific X-ray powder diffraction (XRPD) data, including key diffraction peaks at defined 2-theta values. Precise identification of these peaks is crucial for determining if a sample is Form K.
-
Does CA2949932 prevent the sale of mesalamine for conditions other than inflammatory bowel disease?
While the patent's primary therapeutic claims focus on IBD, the method of manufacturing or composition claims could potentially have broader implications. However, its specific enforcement is most strongly tied to the patented therapeutic uses.
-
Who is the current owner of CA2949932?
The patent is owned by Aptalis Pharma S.A.R.L., which is part of AstraZeneca.
Citations
[1] Aptalis Pharma S.A.R.L. (2015). Pharmaceutical composition comprising mesalamine in crystalline form K and its use (Canadian Patent CA2949932). Canadian Intellectual Property Office. Retrieved from [Official Patent Database]
[2] AstraZeneca. (n.d.). Inflammatory Bowel Disease Treatments. Retrieved from AstraZeneca Corporate Website.
[3] Hardman, J. G., Limbird, L. E., & Molinoff, P. B. (1996). Goodman & Gilman's The Pharmacological Basis of Therapeutics (9th ed.). McGraw-Hill.
[4] Canadian Intellectual Property Office. (n.d.). Patent Law. Retrieved from Innovation, Science and Economic Development Canada Website.
